Oxycodone, hydrocodone top abused opioid list – Clinical Advisor

HealthDay News — About three-quarters of opioid-dependent patients who participated in anonymous surveys and interviews indicated a preference for oxycodone or hydrocodone, researchers have found.

Significantly more users chose oxycodone than hydrocodone — 44.7% vs. 29.4% — mainly because of perceived superior quality, Theodore J. Cicero, PhD, from Washington University in St. Louis, and colleagues reported in PAIN.

They conducted anonymous (more…)

Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent … – PR…

Signature Therapeutics, Inc. (PRNewsFoto/Signature Therapeutics, Inc.)

PALO ALTO, Calif., July 29, 2013 /PRNewswire/ —  Signature Therapeutics, Inc., a development-stage biopharmaceutical company, announced today that it has received no-cost access to contractor resources through the National Center for Advancing Translational Sciences’ Bridging Interventional Development Gaps (BrIDGs) program (part of the NIH) to support development of its extended-release, abuse-deterrent oxycodone, PF614 – (more…)

Intellipharmaceutics Updates Developments on Its Rexista(TM) Oxycodone … – Benzinga

Intellipharmaceutics International Inc. (Nasdaq: IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an update on the following events in its Rexista™ oxycodone development program:

1) The results of the current stage of development and physico-chemical tests to assess abuse-deterrent properties of its Rexista™ oxycodone

2) Stability studies

3) (more…)